Abeona Therapeutics Inc今日宣布，佛罗里达大学健康中心已正式启用，成为Zevaskyn®疗法的又一合格治疗中心。这一举措标志着该公司在扩大Zevaskyn®可及性方面迈出了坚实一步——这家新加入的医疗机构的启用，进一步拓宽了患者获取这一创新疗法的渠道。
作为一家专注于开发严重疾病新型基因疗法的生物制药企业，Abeona Therapeutics此次与佛罗里达大学健康中心的合作，是其持续拓展治疗网络的重要节点。通过将该中心纳入合格治疗中心体系，公司力求为更多有需要的患者提供更便捷的治疗服务。
值得关注的是，Zevaskyn®作为Abeona的核心产品之一，其治疗中心的每一次扩充都具有关键意义。佛罗里达大学健康中心凭借其卓越的临床实力和丰富的患者资源，有望成为Zevaskyn®推广过程中一股不可忽视的推动力量。此次激活，毫无疑问地将为这一疗法在更广泛地区的应用铺平道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.